<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Ligand Pharmaceuticals Incorporated

    Ligand Pharmaceuticals Incorporated

    Ligand is a biopharmaceutical company focused on developing or acquiring technolog...

    Ligand is a biopharmaceutical company focused o...

    Filing Type:    PU
    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd.

    Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...

    Cellect Biotechnology Ltd. was founded in 2011 ...

    Filing Type:    PU
    Affimed Therapeutics

    Affimed Therapeutics

    At Affimed, we are committed to improving outcomes for patients with cancer. Our s...

    At Affimed, we are committed to improving outco...

    Filing Type:    PU
    Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation

    Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...

    Founded in 2006 and headquartered in San Diego,...

    Filing Type:    PU
    MorphoSys AG

    MorphoSys AG

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...

    Filing Type:    PU
    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...

    Avenue Therapeutics, Inc., a Fortress Biotech (...

    Filing Type:    PU
    BioCurity Pharmaceuticals Inc.

    BioCurity Pharmaceuticals Inc.

    BioCurity is a clinical stage biopharmaceutical company with a mission to material...

    BioCurity is a clinical stage biopharmaceutical...

    Amount Raised:    $177,391.00
    Fundraising Status:    EC
    Filing Type:    CF
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.